Rituximab and varlilumab show modest activity. However, CD27 agonist antibodies may elicit meaningful anti-tumor responses when tumors express sufficient intratumoral targets and exhibit existing immune priming.

3 months ago

Journal

CD4 (CD4 Molecule) • CD27 (CD27 Molecule)

Rituxan (rituximab) • varlilumab (CDX 1127)

4ms

Reversibility of Immune Dysfunction Following Pediatric Thermal Injury. (PubMed, J Burn Care Res)

Our hypothesis was immune suppression after pediatric thermal injury is reversible ex-vivo using immunomodulators recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) and varlilumab (CD27-agonist)...Samples co-incubated with GM-CSF significantly increased ex-vivo LPS-induced TNFα while samples containing CD27 increased PHA-induced IL-10 production capacity, in the first 72 h, compared to samples that did not receive immunomodulators. The results of our study identified key markers to discover those most at risk for development of NI and provided early evidence of immunomodulators that may enhance immune function early after pediatric burn injury.

4 months ago

Journal • IO biomarker

TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10) • CD14 (CD14 Molecule) • CD27 (CD27 Molecule) • CSF2 (Colony stimulating factor 2)

varlilumab (CDX 1127)

4ms

A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade. (PubMed, Sci Rep)

HexaBody-CD27 (GEN1053/BNT313) is an investigational novel agonistic CD27 antibody engineered to enhance T-cell costimulation and promote antitumor immunity...In conclusion, HexaBody-CD27 enhanced T-cell activation and effector functions in an FcγR-crosslinking-independent manner, without inducing T-cell depletion. The immune agonist activity of HexaBody-CD27 was potentiated in combination with PD-1 blockade.

4 months ago

Journal • PD(L)-1 Biomarker • IO biomarker

CD8 (cluster of differentiation 8) • CD27 (CD27 Molecule)

5ms

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (clinicaltrials.gov)

P2, N=0, Withdrawn, Merck Sharp & Dohme LLC | N=100 --> 0 | Recruiting --> Withdrawn

5 months ago

Enrollment change • Trial withdrawal

Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin

8ms

DERIVe: DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (clinicaltrials.gov)

P2, N=43, Active, not recruiting, Annick Desjardins, MD | Trial completion date: Mar 2025 --> Mar 2026 | Trial primary completion date: Mar 2025 --> Mar 2026

8 months ago

Trial completion date • Trial primary completion date

MGMT (6-O-methylguanine-DNA methyltransferase) • CCL3 (C-C Motif Chemokine Ligand 3)

temozolomide • varlilumab (CDX 1127)

8ms

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (clinicaltrials.gov)

P2, N=100, Recruiting, Merck Sharp & Dohme LLC | Not yet recruiting --> Recruiting

8 months ago

Enrollment open

Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin

10ms

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003) (clinicaltrials.gov)

P2, N=100, Not yet recruiting, Merck Sharp & Dohme LLC

10 months ago

New P2 trial

Keytruda (pembrolizumab) • Lynparza (olaparib) • carboplatin • paclitaxel • doxorubicin hydrochloride • capecitabine • cyclophosphamide • epirubicin

1year

RiVa: A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma (clinicaltrials.gov)

P1/2, N=26, Completed, University Hospital Southampton NHS Foundation Trust | Active, not recruiting --> Completed | Phase classification: P2a --> P1/2 | Trial completion date: Mar 2024 --> Aug 2024

1 year ago

Trial completion • Phase classification • Trial completion date

CD20 (Membrane Spanning 4-Domains A1)

CD20 expression

Rituxan (rituximab) • varlilumab (CDX 1127)

1year

DIAL: Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas (clinicaltrials.gov)

P2, N=54, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2024 --> Oct 2025

1 year ago

Trial completion date • Combination therapy • Tumor mutational burden • IO biomarker

ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CD27 (CD27 Molecule) • IRF4 (Interferon regulatory factor 4)

BCL6 rearrangement • BCL2 rearrangement

Opdivo (nivolumab) • varlilumab (CDX 1127) • ABP 206 (nivolumab biosimilar)

1year

Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) (clinicaltrials.gov)

P1, N=184, Completed, Merck Sharp & Dohme LLC | Active, not recruiting --> Completed

1 year ago

Trial completion

Keytruda (pembrolizumab) • carboplatin • albumin-bound paclitaxel • pemetrexed

over1year

A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic NSCLC. (PubMed, JTO Clin Res Rep)

Varlilumab in combination with atezolizumab and RT was safe and well tolerated; no additional signal was identified for toxicity. Clinical activity for the combination was modest with 25% of patients with stable disease as the best response.

over 1 year ago

P1 data • Journal • Combination therapy • Metastases

CD27 (CD27 Molecule)

Tecentriq (atezolizumab) • varlilumab (CDX 1127)